
PROTAK™ MZ1

E31P18729

Catalog Number: E31P18729-1, E31P18729-2
Product Name: PROTAK™ MZ1
Amount: 1mg, 5mg
CAS No.: 1797406-69-9
Name: 4R)-N-[14-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-1,13-dioxo-3,6,9-trioxa-12-azatetradec-1-yl]-3-methyl-L-valyl-4-hydroxy-N-[[4-(4-methyl-5-thiazolyl)phenyl]methyl]-L-prolinamide

Molecular Structure:



Purity: >98.00%
Formula: $C_{49}H_{60}ClN_9O_8S_2$
M.W.: 1002.6
Solubility: Soluble in DMSO
Storage/Stability: Store at -20° C
Background: ACY-241 is a new, selective and orally available inhibitor of HDAC6 . Histone deacetylase 6 (HDAC6) is an enzyme that removes acetyl groups from an ε-N-acetyl lysine on a histone, allowing the histones to wrap the DNA more tightly. HDAC6 plays an important role in transcriptional regulation and cell cycle progression.
ACY-241 is a new, selective and orally available HDAC6 inhibitor. In MM and MCL cells, the addition of ACY-241 to either lenalidomide (len) or pomalidomide (pom) resulted in synergistic increases in apoptosis and further reduced the expression of transcription factors MYC and IRF4 [1]. In multiple solid tumor cell lines, combination treatment with ACY-241 and paclitaxel resulted in enhanced inhibition of cell proliferation and increased cell death, compared with either single agent alone .

PROTAK™ is a registered trademark of EnoGene.